MacroGenics CEO Scott Koenig gets the pre-ASCO party started with some encouraging pipeline tidbits — leaving lots of questions for later
Generally, you have to wait and see what abstracts and selected programs get the spotlight at ASCO before investors have a chance to weigh in. But MacroGenics $MGNX CEO Scott Koenig isn’t waiting around to go through official channels for his first nuggets of news. On their Q1 call, the CEO laid out a trail of tidbits from their planned ASCO data releases on Wednesday that rang up a gangbuster response on Wall Street.
Here’s one morsel of information that got a lot of attention:
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.